SensNews March 2020

Sensor100 Page 6 Cepheid has developed an automated molecular test for the qualitative detection of SARS-CoV-2, the virus that causes COVID-19.The test leverages the design principles of its current Xpert® Xpress Flu/RSV cartridge technology, in which multiple regions of the viral genome are targeted.The test can provide rapid detection of the current pandemic coro- navirus SARS-CoV-2 in approximately 45 minutes with less than a minute of hands on time to prepare the sample. Xpert® Xpress SARS-CoV-2 can be utilized in multiple settings where actionable test results are needed to make informed treatment decisions quickly. The test delivers point-of-care results with the same level of performance seen in reference labs. [For Use Under an Emergency Use Authorization (EUA) Only.Test pending submission and review by international regulatory agencies.] The AlphaBiolabs™ IgM-IgG Combined Antibody Rapid Test is one of the world’s first linear flow rapid screening tests for the identification of coronavirus infection.This ac- curate screening test is similar to the type that was used widely by the Chinese Centre for Disease Control and Prevention to identify COVID-19 infections and is now available fromAlphaBiolabs.The single-use qualitative test detects both early and late marker IgG/ IgM antibodies in human finger-prick blood samples in 15 minutes.